President & Chief Executive Officer
Donald McCaffrey is President & Chief Executive Officer of Resverlogix Corp. Don has over 35years of corporate management experience, including over 17 years in drug discovery & development. Don co-founded Resverlogix in 2001 with Dr. Norman Wong. Don’s expertise in corporate operations has attracted an international team of experts to Resverlogix, including world renowned Key Opinion Leaders in the fields of cardiology, endocrinology and nephrology. Lead drug, apabetalone (RVX-208) is well into a Phase 3 clinical trial called 'BETonMACE.' Apabetalone has an 8 year lead on the market as the first epigenetic drug for the reduction of Major Adverse Cardiac Events (MACE). Don has strategically directed Resverlogix in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Shenzhen Hepalink Pharmaceuticals.
Don’s passion lies in supporting non-profit organizations, especially those that support education and the development of future generations of young scientists. Don’s personal donation to the Mount Royal University contributed to the Roderick Mah Centre for Continuous Learning, which supports student facilities within the health and sciences programs. The building is one of North America’s most environmentally sustainable, technologically advanced and designed for learning.
DR. NORMAN C.W. WONG, M.D., FRCP
Chief Scientific Officer & Co-Founder
Dr. Wong's research interest focuses on the molecular actions of hormones related to the regulation of gene expression and pathogenesis of diabetes mellitus. His clinical interest encompasses patients with thyroid disease or diabetes mellitus. His most recent successes have come from uncovering potential therapeutic targets in the field of epigenetics. This area of endeavor stems from his previous training in the field of chromatin structure.
Dr. Wong keeps active in the academic community with speaking engagements at national and international medical conferences. He has been the author and co-author of more than 300 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.
Norman is fluent in Cantonese and an active volunteer in the Calgary Chinese community where he staffs a weekend medical clinic near Chinatown.
A. BRAD CANN, CA
Chief Financial Officer
Brad has more than 20 years of experience in a variety of financial and business roles. Since joining Resverlogix in 2009, Brad has led the Company’s expanding financial activities supporting advancing scientific and clinical development. In addition to overseeing the Company's financial reporting, Brad has been instrumental in the Company's financing and other activities.
Prior to joining Resverlogix, Brad was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust. Prior to his positions with Royal Host, Brad was a business consultant and held senior management positions with several companies including Chief Financial Officer of Sulphur Corporation of Canada Ltd. and Chief Financial Officer of Suntec Pure Water Technologies Inc. Prior thereto, Brad held various positions with Kenway Mack Slusarchuk Stewart Chartered Accountants.
Brad is a Chartered Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.
Brad is an avid cyclist and triathlete.
DR. EWELINA KULIKOWSKI, PH.D
Senior Vice President, Research & Development
Dr. Kulikowski leads all of the research and development activities at Resverlogix Corp. She joined Resverlogix in 2005 as Director of Research and Development and has been involved in the development of lead drug RVX-208 (Apabetalone) from its discovery through to the IND and into clinical development. Dr. Kulikowski has also led projects in oncology, ophthalmology, and vascular inflammation, as well as served as a liaison between the science and business teams. As Director of Business Development and Scientific Affairs, Dr. Kulikowski was involved in various aspects of pipeline development including market, reimbursement and pharmacoeconomic surveys, regulatory affairs, commercial and lifecycle management. Most recently, Dr. Kulikowski has led the Neurodegenerative Program and continues to oversee this area of development. In 2004, she received her Doctorate in Oncology from the University of Calgary, AB.
Ewelina is fluent in Polish and an active member of the Polish community in Calgary including in Polish folk dance, school, and scouting.
DR. MICHAEL SWEENEY, M.D
Senior Vice President, Clinical Development
Dr. Sweeney, a cardiologist with extensive experience in pharmaceutical product development and marketing, oversees the clinical development programs for Resverlogix in cardiovascular disease, diabetes mellitus, chronic kidney disease and other indications.
Dr. Sweeney has an impressive career history, spanning over 30 years in the pharmaceutical industry. This includes 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of Marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was Chief Medical Officer and Vice President of Research and Development at Depomed, Inc. in Silicon Valley. Dr. Sweeney was also the Vice President of Medical Affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina.
Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He is a fellow of the Royal College of Physicians of Edinburgh.
In his spare time Mike enjoys swimming, cycling, football, the cinema and travelling with his family.
KENNETH LEBIODA, BA
Senior Vice President, Business & Corporate Development
Ken has over 30 years of experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access. Ken's past contributions in helping build leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro will provide strategic guidance for the company's technologies in the areas of market analysis, regulatory affairs, pharmacoeconomics, licensing and commercial development.
Ken is an accomplished musician and enjoys travelling with his wife taking their two sons around the world to develop their martial arts skills.
DR. JAN O. JOHANSSON, M.D., PH.D.
Senior Vice President, Medical Affairs
Dr. Johansson has had a distinguished 35 year career in academia and in the pharmaceutical industry of which include small biotechnology and large pharmaceutical companies with expertise in the cardio-metabolic and neurological disease therapeutic area. He has served as Chief Medical Officer at Nuvelo, Inc., VP, Clinical Research and Development at Lipid Sciences, Inc. and was Co-founder, VP, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at the cardiometabolic division of Pharmacia, Sweden, helping bring LOVAZA/OMACOR and FRAGMIN to the market.
Dr. Johansson earned his M.D. and Ph.D.at the Karolinska Institute in Sweden where he led a successful career as a tenured associate professor at the Karolinska Hospital and as a practicing physician. He has published more than 60 peer-review medical articles, and is a member of several scientific organizations including the American Heart Association and the European Atherosclerosis Society.
Jan, a native of Sweden and former semi-professional hockey player, nowadays enjoys bike-riding and loves playing with his grandchildren.
DR. HENRIK C. HANSEN, PH.D.
Vice President, Intellectual Property
Dr. Hansen joined Resverlogix in 2005 and has held a number of roles and responsibilities within the company, including his current position as VP of Intellectual Property. Henrik is the inventor of RVX-208 (apabetalone) and has more than 17 years of experience, from both academia and industry, in basic research, drug discovery, and drug development. His areas of expertise include drug discovery, medicinal chemistry, process development, and manufacturing of drug substances and drug products under cGMP for clinical use.
Henrik holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 65 articles and meeting abstracts and is listed as inventor of 9 patent families.
Outside the office, Henrik is an active runner and nature photographer.
PAUL MOON, CPIR
Vice President, Investor Relations and Communications
Paul joined Resverlogix’s leadership team in July 2018 and brings 25 years of public company experience working in multiple industries, including: technology, financial services, real estate, international mining, and oil and gas. Paul has provided strategic investor relations guidance to senior leadership teams across different industries and has a deep understanding of the capital markets. He has been instrumental in developing investor relations and communications strategies to address multiple stakeholders’ needs and to position companies for success.
Prior to joining Resverlogix, Paul served as the Director of Investor Relations, Corporate Communications and Marketing for Pure Technologies, a company developing innovative solutions that help protect critical water infrastructure around the world. Other posts include Director of Investor Relations for Boardwalk REIT, Canada’s largest residential landlord and serving as an investor relations consultant for public and private companies.